Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
Public ClinicalTrials.gov record NCT00705874. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Open Label, Multicenter, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Dose Limiting Toxicity, Safety and Pharmacokinetics of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will aims to determine the maximum tolerated dose of CGC-11047 when used in individual combinations with gemcitabine, or docetaxel, or bevacizumab, or erlotinib or cisplatin or 5-flurouracil or sunitinib in one of 7 treatment arms. The dose of CGC-11047 will be escalated until the maximum tolerated dose is established.
Study identification
- NCT ID
- NCT00705874
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 172 participants
Conditions and interventions
Conditions
Interventions
- CGC-11047 and gemcitabine Drug
- CGC-11047 and docetaxel Drug
- CGC-11047 and bevacizumab Drug
- CGC-11047 and erlotinib Drug
- CGC-11047 and cisplatin Drug
- CGC-11047 and 5-flurouracil / leucovorin Drug
- CGC-11047 and sunitinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2006 (Type not available)
- Primary completion
- Aug 2011 (Actual)
- Completion
- Sep 2011 (Actual)
- Last update posted
- Jul 21, 2016
2006 – 2011
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rocky Mountain Cancer Centre | Denver | Colorado | — | — |
| Cancer Centres of Florida | Ocoee | Florida | 34761 | — |
| Central Indiana Cancer Centres | Indianapolis | Indiana | 46219 | — |
| Comprehensive Cancer Centres of Nevada | Las Vegas | Nevada | 89169 | — |
| New York Oncology Hematology PC | Albany | New York | 12206 | — |
| Dayton Oncology and Hematology, PA | Kettering | Ohio | 45409 | — |
| Cancer Centres of the Carolinas | Greenville | South Carolina | 29605 | — |
| Texas Oncology, PA | Dallas | Texas | 75246 | — |
| Tyler Cancer Centre | Tyler | Texas | 75702 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Northwest Cancer Specialists - Vancouver Cancer Centre | Vancouver | Washington | 98684 | — |
| North Star Lodge Cancer Centre | Yakima | Washington | 98902 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00705874, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2016 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00705874 live on ClinicalTrials.gov.